Skip to main content
Fig. 4 | Respiratory Research

Fig. 4

From: NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma

Fig. 4

Hierarchical testing strategy for primary and key secondary endpoints. Testing will be performed at a two-sided 5% significance level unless otherwise stated. aA truncated Hochberg adjustment will be used for level 4. As such, the higher of the two level 4 p values will be evaluated at a 3.75% significance level (two-sided). If it is significant at the 3.75% level, both level 4 null hypotheses will be rejected, and testing will proceed to level 5. If it is not significant at the 3.75% level, the lower of the two level 4 p values will be evaluated at a 2.5% significance level (two-sided). If significant, the relevant null hypothesis will be rejected, and testing will proceed to level 5. bIf both null hypotheses are rejected at level 4, level 5 will be tested at a two-sided 5% significance level. If only one null hypothesis is rejected at level 4, level 5 will be tested at a two-sided 1.25% significance level. AAER, annualized asthma exacerbation rate; ACQ-6, Asthma Control Questionnaire-6; AQLQ(S) + 12, Asthma Quality of Life Questionnaire standardized for patients 12 years and older; FEV1, forced expiratory volume in 1 s

Back to article page